The news: Pushed by consumer demand and a shortage of the brand-name GLP-1 medications, WeightWatchers (WW) has joined a growing list of companies that will be offering compounded semaglutide (marketed by Novo Nordisk as Ozempic and Wegovy) to its members.
- Last year, WW entered the weight loss drug market when it acquired Sequence, a telehealth company that prescribes the meds.
- Starting at $189 per month, the new offering is an add-on to WW’s existing weight management program, which includes access to clinicians, dieticians, and treatments.
- Shares of WW soared ~50% following the announcement, but are still down nearly 80% for the year.